Systematic review evaluates cardiovascular adverse events linked to EGFR inhibitors in NSCLC patients, suggesting increased risks with third generation drugs.
Key Points
Third generation EGFR tyrosine kinase inhibitors significantly increase cardiovascular adverse events compared to placebo.
The odds ratio for third generation drugs like osimertinib is 2.53, indicating a high risk of cardiac events in patients.
The systematic review analyzed 89 trials involving almost 30,000 participants, providing robust evidence for the findings.
Combination therapies with antiangiogenesis and EGFR inhibitors also show heightened cardiovascular risks, especially with third generation drugs.